|
Match
|
Document |
Document Title |
|
|
5759818 |
N-terminal CTP extended pharmaceutical peptides and proteins
"Partial" and "complete" CTP units are used to modify biologically active proteins and peptides at the aminoterminus to alter their clearance patterns. "Complete" CTP units have the amino acid...
|
|
|
5756084 |
Human stromal derived factor 1α and 1β
The polypeptides of the present invention are produced and secreted in pro-B cells, so they may be used for diseases relating to undergrown or abnormal proliferation of hematopoietic cells,...
|
|
|
5753203 |
CD30 ligand conjugates
There is disclosed a polypeptide (CD30-L) and DNA sequences, vectors and transformed host cells useful in providing CD30-L polypeptides. The CD30-L polypeptide binds to the receptor known as CD30,...
|
|
|
5747072 |
Adenoviral-mediated gene transfer to synovial cells in vivo
This invention provides recombinant adenoviral vectors having an expression control sequence operatively linked to a gene that encodes an anti-inflammatory polypeptide or that produces on...
|
|
|
5738849 |
Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
The present invention relates to fusion molecules composed of human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally joined to a second colony stimulating factor (CSF),...
|
|
|
5736387 |
Envelope fusion vectors for use in gene delivery
The invention provides retroviral vectors which can be used for directing gene delivery to a specific sub-population of mammalian cells. The vectors comprise chimeric targeting proteins which...
|
|
|
5728377 |
Methods and compositions incorporating IP-10
The present invention discloses the correct processing of IP-10, a myelosuppressive protein produced by certain cells such as keratinocytes, monocytes and human endothelial cells upon stimulation...
|
|
|
5728804 |
Use of cyclodextrins for protein renaturation
A method for renaturing a denatured protein is provided comprising contacting a solution or suspension of said denatured protein in a detergent-free liquid medium with an amount of a cyclodextrin...
|
|
|
5728552 |
DNA encoding a fusion protein comprising a viral antigen and lymphokine
Disclosed are (1) a fused protein obtained by combining an antigen used for vaccine and a lymphokine by the application of gene engineering, (2) a recombinant DNA containing a nucleotide sequence...
|
|
|
5723318 |
DNA coding for megakaryocyte potentiator
Genes coding for a polypeptide having a human megakaryocyte potentiator activity, recombinant vectors containing said genes, host cells that have been transformed with said recombinant vectors, and...
|
|
|
5714588 |
Enhancement of cellular attachment using H3 protein
A method of producing recombinant transforming growth factor β-induced H3 protein and the use of this protein to accelerate wound healing. H3 promoted adhesion of human dermal fibroblasts to...
|
|
|
5705349 |
Methods for preparing polynucleotides encoding orphan receptor ligands
Methods for obtaining cells that produce a ligand for an orphan receptor and methods for preparing polynucleotide molecules that encode ligands for orphan receptors are disclosed. The methods...
|
|
|
5703206 |
Macrophage inflammatory protein 2 (MIP-2)
An inflammatory cytokine is disclosed which has been isolated from cells that have been incubated with a stimulator material. The inflammatory cytokine comprises a protein that is capable of...
|
|
|
5702920 |
DNAS encoding human macrophage migration inhibition factor related peptides
The invention concerns polypeptides related to human macrophage migration inhibition factor, in particular the polypeptides called MRP-8 and MRP-14, processes for their preparation, mRNAs, DNAs and...
|
|
|
5702919 |
DNA encoding canine granulocyte macrophage colony stimulating factor
Canine granulocyte macrophage colony stimulating factor (caGM-CSF) corresponding to that found in canine serum and/or tissues, structural variants thereof, genes that encode these materials,...
|
|
|
5696250 |
DNA encoding megakaryocyte growth and development factor analogs
MGDF analogs having one or more changed glycosylation sites as compared to a naturally occuring MGDF sequence of a corresponding number of amino acids are disclosed. The invention also relates to...
|
|
|
5695953 |
DNA that encodes a tumor necrosis factor inhibitory protein and a recombinant method of production
Tumor Necrosis Factor (TNF) Inhibitory Protein is isolated and substantially purified and the DNA that encodes the TNF inhibitory protein, vectors, host cells, and a recombinant method for...
|
|
|
5686265 |
Leukocyte adhesion receptors
This invention concerns the cloning of the alpha-subunit of the p150,95 leukocyte adhesion receptor molecule. The invention also concerns the alpha-subunit of p150,95, as well as fragments of this...
|
|
|
5683688 |
Unglycosylated recombinant human lymphotoxin polypeptides and compositions
Biologically active lymphotoxin polypeptides are synthesized in recombinant cell culture. Novel nucleic acid and vectors incorporating same are provided. The compositions and processes herein...
|
|
|
5681562 |
Lymphokine gene therapy of cancer
A novel method of tumor immunotherapy is described comprising the genetic modification of cells resulting in the secretion of cytokine gene products to stimulate a patient's immune response to...
|
|
|
5681723 |
Mutant interleukin 6 with improved biological activity over wild interleukin 6
The present invention is drawn to mutant interleukin 6, which has the amino acid arginine in position 176, replacing serine in position 176 with wild-type interleukin 6. The mutant interleukin 6 of...
|
|
|
5681720 |
DNA encoding human granulocyte colony stimulating factor plasmids and host cells comprising same, and methods of expressing the encoded polypeptide
Novel hG-CSF polypeptide derivatives having an amino acid sequence derived from the amino acid sequence of the human granulocyte colony stimulating factor polypeptide by substitution of at least...
|
|
|
5681719 |
DNA encoding N- and C- terminally truncated colony stimulating factor-1 variants
DNA for new forms of CSF-1 are provided which relate to N-terminal and C-terminal truncations. Specifically, N-∇3 terminal truncations of the short and long forms of CSF-1 have been found to be...
|
|
|
5676941 |
Methods of enhancing bone marrow transplantation and treating burn wounds comprising administering human pluripotent granulocyte colony-stimulating factor
Disclosed are novel polypeptides possessing part or all of the primary structural conformation and one or more of the biological properties of a mammalian (e.g., human) pluripotent granulocyte...
|
|
|
5674703 |
Episomal vector systems and related methods
An episomal vector sytem and methods for use in gene therapy in humans and animals. The vector contains a papilloma virus origin of replication, a vector maintenance sequence, a first promoter...
|
|
|
5672343 |
N- 3 deletion mutants of the long form of CSF-1
New forms of CSF-1 are provided which relate to N-terminal truncations. Specifically, N-∇3 terminal truncations of the long form of CSF-1 have been found to be particularly advantageous. These...
|
|
|
5670146 |
Pharmacological preparations comprising human pluripotent hematopoietic colony stimulating factor
Highly purified Pluripotent hematopoietic colony-stimulating factor (pluripotent CSF), a glycoprotein (MW 19,600) constitutively produced by human tumor cells has been highly purified from low...
|
|
|
5665863 |
Polypeptides having granulocyte colony stimulating activity, their preparation and pharmaceutical compositions containing them
New polypeptides having granulocyte colony stimulating activity, preparation thereof and pharmaceutical compositions containing said polypeptides.
|
|
|
5658754 |
Cell-free synthesis and isolation of novel genes and polypeptides
A method for the cell-free synthesis and isolation of novel genes and polypeptides is provided. Within one embodiment, an expression unit is constructed onto which semi-random nucleotide sequences...
|
|
|
5651963 |
Heterodimers forms of CSF-1 and pharmaceutical compositions thereof
The present invention relates to the production of CSF-1 heterodimers and pharmaceutical formulations of the heterodimers. The heterodimers can be formed using CSF-1 monomers that have variations...
|
|
|
5652353 |
DNAs encoding tumor necrosis factor-α muteins
It is an object of this invention to provide a human Tumor Necrosis Factor mutein or a pharmaceutically acceptable salt thereof characterized in that the TNF sequence is changed by a deletion,...
|
|
|
5650297 |
DNA encoding human colony-stimulating factors
This invention relates to a biologically active recombinant human M-CSF obtained by expressing a human M-CSF gene coding for the amino acid sequence of the formula (1) in its entirety or devoid of...
|
|
|
5646154 |
Pharmaceutical compositions for inhibiting the formation of tumor necrosis factor
Quinazoline compounds represented by general formula (1) or (2) possess an activity of significantly inhibiting the production or secretion of a tumor necrosis factor and are useful as drugs for...
|
|
|
5643563 |
N-∇3 deletion mutants of the short form of CSF-1
New forms of CSF-1 are provided which relate to N-terminal truncations. Specifically, N-∇3 terminal truncations of the short form of CSF-1 have been found to be particularly advantageous. These...
|
|
|
5641655 |
Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
DNA constructs useful in the production of thrombopoietin are disclosed. In general, the DNA constructs comprise a first DNA segment encoding a fusion of an amino-terminal secretory peptide joined...
|
|
|
5637477 |
Recombinant protein production and insect cell culture and process
A process has been developed for recombinant production of selected polypeptides using transformed insect cells cultured in a horizontally rotating culture vessel modulated to create low shear...
|
|
|
5635599 |
Fusion proteins comprising circularly permuted ligands
The present invention provides for circularly permuted ligands which possess specificity and binding affinity comparable to or greater than the specificity and binding affinity of the original...
|
|
|
5633149 |
Polynucleotide encoding novel chemokine expressed in inflamed adenoid
The present invention provides nucleotide and amino acid sequences that identify and encode a novel expressed chemokine (ADEC) from inflamed adenoid tissue. The present invention also provides for...
|
|
|
5633146 |
Method for producing recombinant proteins and host cells used therein
Novel genetically engineered yeast strains of genus Kluyveromyces lactis, their preparation, and the use thereof for producing recombinant proteins, are described.
|
|
|
5627267 |
Cytokine designated elk ligand
elk ligand (elk-L) polypeptides as well as DNA sequences, vectors and transformed host cells useful in providing elk-L polypeptides. The elk-L polypeptide binds to a cell surface receptor that is a...
|
|
|
5616555 |
Crystalline r-h-GM-CSF and method
This invention provides a crystalline form of recombinant human granulocyte-macrophage colony-stimulating factor (r-h-GM-CSF) and methods for making such crystals.
|
|
|
5616477 |
Fusion proteins comprising GM-CSF and antigens and their expression in yeast
Novel fusion proteins that enhance the immune response of an antigen are efficiently expressed and secreted by yeast host cells. The fusion proteins are recombinantly made by fusing the 3'-end of...
|
|
|
5614184 |
Recombinant human erythropoietin mutants and therapeutic methods employing them
DNA encoding modified, secretable erythropoietin proteins whose ability to regulate the growth and differentiation of red blood cell progenitors are different from the wildtype recombinant...
|
|
|
5612195 |
Recombinant production of a human interferon (IFN)-gamma antagonist cytokine
A cytokine that is a specific antagonist of induction by interferon-gamma of the expression of class II histocompatibility antigens at the cell surface is disclosed. The cytokine is naturally...
|
|
|
5610279 |
Human TNF receptor
The present invention is concerned with non-soluble proteins and soluble or insoluble fragments thereof, which bind TNF, in homogeneous form, as well as their physiologically compatible salts,...
|
|
|
5605817 |
DNA encoding chemokine expressed in fetal spleen
The present invention provides nucleotide and amino acid sequences that identify and encode a novel expressed chemokine (FSEC) from human fetal spleen cells. The present invention also provides for...
|
|
|
5602008 |
DNA encoding a liver expressed chemokine
The present invention provides nucleotide and amino acid sequences that identify and encode novel expressed chemokines (ECs) from liver and pituitary gland tissues. The present invention also...
|
|
|
5602007 |
Recombinant DNA molecules
This invention provides a DNA sequence coding for a mammalian granulocyte macrophage colony stimulating factor (GM-CSF), a method of obtaining same, vectors and hosts harboring same. The sequence...
|
|
|
RE35450 |
Soluble human interleukin-1 receptors, compositions and method of use
Soluble human Interleukin-1 receptor proteins (shuIL-1Rs) and methods of using shuIL-1Rs to suppress immune or inflamatory responses in a mammal.
|
|
|
5599690 |
Control of norleucine incorporation into recombinant proteins
Norleucine incorporation into recombinant gene products may be inhibited by culturing the cells expressing the gene products in media comprising a high level of leucine and/or methionine, or by...
|